Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Irish Journal of Medical Science (1971 -)
Published in: Irish Journal of Medical Science (1971 -) 2/2018

01-05-2018 | Original Article

Surgical management of splenic marginal zone lymphoma

Authors: N. D. Kennedy, G. N. Lê, M. E. Kelly, T. Harding, K. Fadalla, D. C. Winter

Published in: Irish Journal of Medical Science (1971 -) | Issue 2/2018

Login to get access

Abstract

Objectives

Splenic marginal zone lymphoma (SMZL) is a rare indolent B-cell lymphoma with variable prognosis. As a result, there is sparse knowledge on the role of splenectomy and best management approaches. We aim to explore management strategies and outcomes amongst the cohort of SMZL patients at our centre.

Method

A retrospective review of all splenectomies performed at a tertiary referral unit over a 23-year period was assessed. Immunohistochemical and pathological results of splenic samples, bone marrow biopsies, and peripheral blood were compiled. Operative management, surgical, and survival outcomes were assessed. Prognostic stratifications were applied and survival rates were calculated.

Results

Eight cases of SMZL from a database of 693 splenectomies were identified. All patients had intermediate/high-risk disease. All patients underwent splenectomy with one patient receiving preoperative rituximab. All patients had progression-free survival and resolution of disease.

Conclusion

Based on the data obtained, current practice requires defined guidelines and centralised care.
Literature
1.
De Pasquale A, Paterlini P, Di Francesco A, Vecchio L, Quaglino D (1986) Follicular lymphomas with predominant splenic involvement: report of two cases. Tumori 72(1):109–115
2.
Swerdlow SH, Campo E, Piler SA et al (2008) WHO classification of tumours of haematopoietic and lymphoid tissues, vol 2. IARC Press, Lyons
3.
Arcaini L, Rossi D, Paulli M (2016) Splenic marginal zone lymphoma: from genetics to management. Blood 127(17):2072–2081CrossRefPubMed
4.
Kalpadakis C, Pangalis GA, Angelopoulou MK et al (2017) Treatment of splenic marginal zone lymphoma. Best Pract Res Clin Haematol 30(1–2):139–148
5.
Matutes E, Oscier D, Montalban C et al (2008) Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia 22(3):487–495
6.
Liu L, Wang H, Chen Y et al (2013) Splenic marginal zone lymphoma: a population-based study on the 2001-2008 incidence and survival in the United States. Leuk Lymphoma 54(7):1380–1386
7.
Arcaini L, Bruno R (2010) Hepatitis C virus infection and antiviral treatment in marginal zone lymphomas. Curr Clin Pharmacol 5(2):74–81CrossRefPubMed
8.
Arcaini L, Paulli M, Boveri E et al (2004) Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles. Cancer 100(1):107–115
9.
10.
Joshi M, Sheikh H, Abbi K et al (2012) Marginal zone lymphoma: old, new, targeted, and epigenetic therapies. Ther Adv Hematol 3(5):275–290
11.
Arcaini L, Rossi D, Lucioni M et al (2015) The NOTCH pathway is recurrently mutated in diffuse large B-cell lymphoma associated with hepatitis C virus infection. Haematologica 100(2):246–252
12.
Du M-Q (2015) Pathogenesis of splenic marginal zone lymphoma. Pathogenesis 2(4):11–20CrossRef
13.
Arcaini L, Lazzarino M, Colombo N et al (2006) Splenic marginal zone lymphoma: a prognostic model for clinical use. Blood 107(12):4643–4649
14.
Olszewski AJ, Castillo JJ (2013) Survival of patients with marginal zone lymphoma. Cancer 119(3):629–638CrossRefPubMed
15.
Montalban C, Abraira V, Arcaini L et al (2011) Stratification approach for splenic marginal zone lymphoma based on hemoglobin, platelet count, high LDH and extrahilar lymphadenopathy: the HPLL/ABC system. Blood 118(21):1538
16.
Montalban C, Abraira V, Arcaini L et al (2014) Simplification of risk stratification for splenic marginal zone lymphoma: a point-based score for practical use. Leuk Lymphoma 55(4):929–931
17.
Kalpadakis C, Pangalis GA, Angelopoulou MK et al (2014) Validation of the simplified prognostic score for splenic marginal zone lymphoma of the splenic marginal zone lymphoma working group. Leuk Lymphoma 55(11):2640–2642
18.
Bennett M, Schechter GP (2010) Rituximab monotherapy in splenic marginal zone lymphoma instead of splenectomy. Br J Haematol 149:45
19.
Kalpadakis C, Pangalis GA, Vassilakopoulos TP et al (2014) Treatment of splenic marginal zone lymphoma: should splenectomy be abandoned? Leuk Lymphoma 55(7):1463–1470
20.
Else M, Marín-Niebla A, de la Cruz F et al (2012) Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma. Br J Haematol 159(3):322–328
21.
Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240(2):205–213CrossRefPubMedPubMedCentral
22.
Ponzoni M, Kanellis G, Pouliou E et al (2012) Bone marrow histopathology in the diagnostic evaluation of splenic marginal-zone and splenic diffuse red pulp small B-cell lymphoma: a reliable substitute for spleen histopathology? Am J Surg Pathol 36(11):1609–1618
23.
Thieblemont C, Nasser V, Felman P et al (2004) Small lymphocytic lymphoma, marginal zone B-cell lymphoma, and mantle cell lymphoma exhibit distinct gene-expression profiles allowing molecular diagnosis. Blood 103(7):2727–2737
24.
Sun Q,  Zhang PH, Liu EB et al (2013) Clinicopathologic features and differential diagnosis of splenic B-cell marginal zone lymphoma involving bone marrow. Zhonghua Bing Li Xue Za Zhi 42(4):234–238
25.
Gazzola A, Sabattini E, Mannu C et al (2011) Partial nodal involvement by marginal zone lymphoma. Use of IGK gene rearrangement analysis in diagnostic work-up. Pathologica 103(1):14–18
26.
Munari E, Rinaldi M, Ambrosetti A et al (2012) Absence of TCL1A expression is a useful diagnostic feature in splenic marginal zone lymphoma. Virchows Arch 461(6):677–685
27.
Khodzhibekova MM, Tiutin LA, Kostenikov NA et al (2015) 18F–FDG positron emission tomography in the diagnosis and staging of marginal zone non-Hodgkin lymphomas. Vestn Rentgenol Radiol 1:16–21
28.
Romano C, Sellitto A, Chiurazzi F et al (2015) Clinical and phenotypic features of CD5-negative B cell chronic lymphoproliferative disease resembling chronic lymphocytic leukemia. Int J Hematol 101(1):67–74
29.
Baseggio L, Traverse-Glehen A, Petinataud F et al (2010) CD5 expression identifies a subset of splenic marginal zone lymphomas with higher lymphocytosis: a clinico-pathological, cytogenetic and molecular study of 24 cases. Haematologica 95(4):604–612
30.
Savilo E, Campo E, Mollejo M et al (1998) Absence of cyclin D1 protein expression in splenic marginal zone lymphoma. Mod Pathol 11(7):601–606
31.
Matutes E (2007) Splenic marginal zone lymphoma with and without villous lymphocytes. Curr Treat Options in Oncol 8(2):109–116CrossRef
32.
Gutierrez-Civicos R, Hurtado AM, Torres-Moreno D et al (2017) Rituximab response in follicular lymphoma is associated with the rs20575 polymorphism in TRAILR1 extrinsic apoptosis trigger. Pharmacogenet Genomics 27(2):70–77
33.
Bennett M, Schechter GP (2010) Treatment of splenic marginal zone lymphoma: splenectomy versus rituximab. Semin Hematol 47(2):143–147CrossRefPubMed
34.
Tsimberidou AM, Catovsky D, Schlette E et al (2006) Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. Cancer 107(1):125–135
35.
Perrone S, D’Elia GM, Annechini G et al (2016) Splenic marginal zone lymphoma: prognostic factors, role of watch and wait policy, and other therapeutic approaches in the rituximab era. Leuk Res 44:53–60
36.
Lenglet J, Traullé C, Mounier N et al (2014) Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment. Leuk Lymphoma 55(8):1854–1860
37.
Thieblemont C, Felman P, Berger F et al (2002) Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients. Clin Lymphoma 3(1):41–47
38.
Xing KH, Kahlon A, Skinnider BF et al (2015) Outcomes in splenic marginal zone lymphoma: analysis of 107 patients treated in British Columbia. Br J Haematol 169(4):520–527
39.
Davidson RN, Wall RA (2001) Prevention and management of infections in patients without a spleen. Clin Microbiol Infect 7(12):657–660CrossRefPubMed
40.
Schreiber DP, Jacobs C, Rosenberg SA et al (1985) The potential benefits of therapeutic splenectomy for patients with Hodgkin's disease and non-Hodgkin’s lymphomas. Int J Radiat Oncol Biol Phys 11(1):31–36
Metadata
Title
Surgical management of splenic marginal zone lymphoma
Authors
N. D. Kennedy
G. N. Lê
M. E. Kelly
T. Harding
K. Fadalla
D. C. Winter
Publication date
01-05-2018
Publisher
Springer London
Published in
Irish Journal of Medical Science (1971 -) / Issue 2/2018
Print ISSN: 0021-1265
Electronic ISSN: 1863-4362
DOI
https://doi.org/10.1007/s11845-017-1689-6

Other articles of this Issue 2/2018

Irish Journal of Medical Science (1971 -) 2/2018 Go to the issue

Original Article

Adductor canal block in combination with posterior capsular infiltration on the pain control after TKA

Case Based Review

Intravascular large B-cell lymphoma presenting clinically as rapidly progressive dementia

Historical and Literary

Step by step guide to do a systematic review and meta-analysis for medical professionals

Original Article

Comparison of abdominal, vaginal, and laparoscopic hysterectomies in a tertiary care hospital in Turkey

Brief Report

Analysis of the outpatient lumbar puncture service in a tertiary hospital

Letter to the Editor

Pituitary plasmacytoma—a rare presentation of multiple myeloma
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits